Product Details

Verfeno Capsules meet Indian Pharmacopoeia (IP) standards for the management of dyslipidaemia. Specifically, each capsule delivers Fenofibrate IP at 160mg. As a result, it offers effective lipid-lowering therapy for patients with elevated triglycerides and abnormal cholesterol levels.

The capsules contain:

• Fenofibrate IP (160mg) – A fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPAR-α). Consequently, it reduces triglyceride and LDL cholesterol levels while increasing HDL cholesterol, improving the overall lipid profile.

Physicians prescribe Verfeno for the management of hypertriglyceridaemia, mixed dyslipidaemia, and as an adjunct to diet in patients with elevated cholesterol who have not responded adequately to lifestyle changes alone. In addition, its once-daily oral dosing supports simple, sustainable long-term lipid management. Because of this profile, Verfeno suits cardiology and general practice settings managing chronic dyslipidaemia and cardiovascular risk reduction.

Key Features:

• Overall, this IP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the oral capsule format supports easy, once-daily dosing
• Furthermore, each capsule delivers precise, validated dosage accuracy at 160mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies